Skip to content

Effect of different energy levels of micropulse transscleral cyclophotocoagulation for the treatment of refractory glaucoma: A prospective randomized comparative study

Effect of different energy levels of micropulse transscleral cyclophotocoagulation for the treatment of refractory glaucoma: A prospective randomized comparative study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210530004
Enrollment
36
Registered
2021-05-30
Start date
2021-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compare the efficacy of different energy levels of micropulse transscleral cyclophotocoagulation on intraocular pressure reduction in refractory glaucoma Micropulse Cyclophotocoagulation Laser treatment Intraocular pressure Glaucoma

Interventions

Laser system- Vitra 810 Subliminal Quantel Medical laser Probe- Subcylo probe (Cournon dAuvergne Cedex France) Categorized patients into two groups (1 to 1) using computer generated block of four ran
Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery
Micropulse transscleral cyclophotocoagulation group 1,Micropulse transscleral cyclophotocoagulation group 2

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Refractory glaucoma patients (defined as glaucoma patients with uncontrolled IOP equal or more than 21 mm Hg at least 3 months despite maximally tolerated topical antiglaucoma medications, with or without oral antiglaucoma medications, and previous surgical therapy if any.) 2. BCVA from 20/20 to PL 3. Age equal or mote than 18 years old and equal or less than 80 years old 4. In case of bilateral refractory glaucoma, the eye which has higher IOP or more aggressive symptoms will be chosen

Exclusion criteria

Exclusion criteria: 1. Previous intraocular surgery within 2 months 2. Any sign of ocular infection or inflammation 3. Having an extended scleral thinning for more than 1 clock hour 4. Pregnancy 5. Patients who cannot be performed local anesthesia

Design outcomes

Primary

MeasureTime frame
Intraocular pressure Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure applanation tonometer (Haag-Streit AG, Koeniz, Switzerland)

Secondary

MeasureTime frame
Best corrected visual acuity Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure ETDRS chart,Anterior chamber cell Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure Standardization of Uveitis Nomenclature (SUN) grading scheme for anterior chamber cells ,Cornea examination Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure Haag-Streit BQ 900 Table LED Slit Lamp ,Fundus examination Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure Haag-Streit BQ 900 Table LED Slit Lamp ,number of topical and systemic anti-glaucoma medications Pre-pocedure and 1 week, 1month, 2 months, 3 months, and 6 months post-procedure Out pateint record

Countries

Thailand

Contacts

Public ContactYarnarin Papassornsiri

Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University

yarnarin.pps@gmail.com0859207771

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026